Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Advanced Cancer Clinical Trial

Official title:

Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03900442
• Other study ID #: PTX-100-PD-012017
• Status: Recruiting
• Phase: Phase 1
• Start date: September 1, 2019
• Est. completion date: April 30, 2023

Study information

• Verified date: September 2021
• Source: Prescient Therapeutics, Ltd.
• Contact: Leanne West
• Email: lwest[@]ptxtherapeutics.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, non-randomized study to evaluate the PD, PK, and safety of 500 to 2000 mg/m2 PTX-100 in patients with advanced malignancies.

PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles unless toxicity is observed.

Dose escalation is complete and the expansion is open and actively recruiting PTCL patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: April 30, 2023
• Est. primary completion date: April 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Biopsy proven multiple myeloma (MM), peripheral T-cell lymphoma (CTCL, AITL or PTCL-NOS), colo-rectal cancer (CRC), pancreas cancer (PANC), or diffuse gastric cancer (DGC)

2. Must have a relapsed or refractory advanced malignancy for which no standard therapy exists.

3. Must have at least 6 unstained slides of archived formalin-fixed, paraffin-embedded tumor tissue available for genotyping studies; if insufficient or no archived tissue is available, a fresh tumor biopsy within 30 days prior to Cycle 1/Day 1 is mandatory.

4. Age = 18 years

5. ECOG performance status = 2

6. Adequate hematological function: absolute neutrophil count (ANC) = 1000/mm3, platelet count = 50,000 mm3

7. Adequate hepatic function: total bilirubin = 1.5 times the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 times ULN (patients with liver metastases may be enrolled with elevated hepatic function based on Medical Monitor and Investigator review and agreement)

8. Adequate renal function: measured, calculated or estimated creatinine clearance of = 50 mL/min

9. Female patients of childbearing potential must have a negative serum pregnancy test at screening and agree to use dual methods of contraception. Male patients must use an effective barrier method of contraception if sexually active with a female of childbearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or postmenopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose.

10. Informed consent (current IRB approved version) must be obtained from the patient or legally authorized representative prior to any study-related procedures.

Exclusion Criteria:

1. Radiation, chemotherapy, immunotherapy, or any other approved anticancer therapy = 2 weeks prior to study treatment

2. Participation in another interventional investigational drug study within 4 weeks prior to enrollment

3. Concurrent radiation, chemotherapy, immunotherapy, or any other approved or investigational anticancer therapeutic (Patients are allowed to receive = 10 mg/day corticosteroids for the treatment of non malignant disorders.)

4. Myocardial infarction within 6 months before screening, New York Heart Association Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities

5. Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose (Patients with controlled infection or on prophylactic antibiotics are permitted in the study.)

6. Known to be HIV seropositive

7. Known active hepatitis A, B, or C infection or known to be positive for HCV RNA or HBsAg (HBV surface antigen)

8. Grade > 2 peripheral neuropathy at screening

9. Previous allogeneic transplant within the past 6 months or evidence of clinically significant graft-versus-host disease (if prior bone marrow transplant)

10. Any history of malignancy, other than that treated in this study, unless the patient has remained free of the disease for over 3 years (except for properly treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast)

11. Any active medical or psychiatric illness that, in the judgement of the investigator, may interfere with adherence to the protocol

12. Any malignancy with CNS involvement

13. History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTX-100

14. Female patients who are pregnant or lactating

Related Conditions & MeSH terms

• Advanced Cancer
• Neoplasms
• PTCL

Intervention

Drug:
• PTX-100
Doses of 500 to 2000 mg/m2 will be administered.

Locations

Country	Name	City	State
Australia	Peninsula & South Eastern Haematology and Oncology Group	Frankston	Victoria
Australia	Epworth Healthcare	Melbourne	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Prescient Therapeutics, Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (RAP-1)	PD endpoints will be based on analysis of level of RAP-1 geranylgeranylation proteins in PBMNCs and tumor biopsies:	One Cycle (cycle = 14 days)
Primary	Investigate the time- and dose-dependent PD of multiple doses of PTX-100 in patients with advanced malignancies (PD endpoints)	PD endpoints will be based on analysis of the level of DJ2 farnesylation proteins in PBMNCs and tumor biopsies:	One Cycle (cycle = 14 days)
Primary	Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (cmax)	Pharmacokinetics will be evaluated by PK parameters calculated from plasma concentrations of PTX 100. Individual and mean plasma concentrations of PTX-100 versus time as well as individual and mean PK parameters will be determined, for the following: • Maximum observed plasma concentration (Cmax)	One Cycle (cycle = 14 days)
Primary	Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (Tmax)	Pharmacokinetics will be evaluated by PK parameters calculated from plasma concentrations of PTX 100. Individual and mean plasma concentrations of PTX-100 versus time as well as individual and mean PK parameters will be determined, for the following: • Time to maximum observed plasma concentration (Tmax)	One Cycle (cycle = 14 days)
Primary	Investigate the time- and dose-dependent PK of multiple doses of PTX-100 in patients with advanced malignancies (half life)	Pharmacokinetics will be evaluated by PK parameters calculated from plasma concentrations of PTX 100. Individual and mean plasma concentrations of PTX-100 versus time as well as individual and mean PK parameters will be determined, for the following: • Apparent elimination half-life (t1/2)	One Cycle (cycle = 14 days)